Results 141 to 150 of about 17,989 (193)

Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis. [PDF]

Rheumatology (Oxford)
Junek M, Fussner LA, Mendel A, Jayne D, Merkel PA, Walsh M.   +5 more
europepmc   +1 more source

Predicting prognosis in ANCA-associated vasculitis with kidney involvement. [PDF]

Clin Kidney J
Maalouli C, Aydin S, Collard A, Cambier JF, Dejardin A, Georges B, Gillerot G, Vanderperren B, Vandooren AK, Jadoul M, Morelle J, Demoulin N, UCLouvain Kidney Disease Network .   +12 more
europepmc   +1 more source

Repeat kidney biopsy reveals new-onset IgA nephropathy in a patient with ANCA-associated vasculitis. [PDF]

CEN Case Rep
Iwami S, Eriguchi M, Kosugi T, Furuyama R, Kitamura S, Tanabe K, Matsui M, Samejima KI, Tsuruya K.   +8 more
europepmc   +1 more source

Avacopan for the Treatment of ANCA-Associated Vasculitis

New England Journal of Medicine, 2021
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a ...
Peter Merkel, David Jayne, Pirow Bekker   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Biologics for ANCA-Associated Vasculitis

Inflammation & Allergy-Drug Targets, 2014
The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of necrotizing vasculitides with a potential fatal outcome. Conventional therapy is based on the use of glucocorticoids (GCs) and cyclophosphamide (CYC), which is associated with severe toxic effects and is unable to control the disease activity in some refractory ...
Murgia G, FIRINU, DAVIDE, MANCONI, PAOLO EMILIO, DEL GIACCO, STEFANO   +3 more
openaire   +3 more sources

The Future of ANCA-associated Vasculitis

Rheumatic Disease Clinics of North America, 2010
The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient
Julia U, Holle, Stefan, Wieczorek, Wolfgang L, Gross   +2 more
openaire   +2 more sources